Here are five updates on GI companies from the past week.
Takeda is considering submitting a bid for British drugmaker Shire, to expand its U.S. presence.
The European Commission approved Takeda and TiGenix's perianal fistulas drug Alofisel.
Protagonist Therapeutics discontinued the phase 2b study of its ulcerative colitis drug, PTG-100, after the trial was deemed too futile to continue.
Pfizer will fund the American Gastroenterological Association's Young Investigator Pilot Research Awards in Inflammatory Bowel Disease.
AbbVie's Vice President of U.S. Immunology Mark Stenhouse is joining Exact Sciences as president of the company's Cologuard product, effective April 2.